Central Nervous System News and Research

RSS

Positive results from laquinimod Phase III ALLEGRO study in multiple sclerosis to be presented at AAN

Teva Pharmaceutical Industries Ltd. and Active Biotech announced today results from the two-year Phase III ALLEGRO study of laquinimod, an oral, once-daily, investigational immunomodulator for the treatment of relapsing forms of multiple sclerosis (MS). These data will be presented as late-breaking research at the Annual Meeting of the American Academy of Neurology (AAN).

12 Apr 2011

Epilepsy medication USL255 associated with less fluctuation in plasma levels compared to topiramate IR

Upsher-Smith Laboratories today announced the presentation of data indicating that once daily administration of USL255, a proprietary extended-release (ER) formulation of the epilepsy medication topiramate, was associated with less fluctuation in topiramate plasma levels compared to immediate-release (IR) topiramate administered twice daily in healthy volunteers.

12 Apr 2011

Positive top-line results from Biogen BG-12 Phase 3 trial in RRMS

Biogen Idec announced today positive top-line results from DEFINE, the first of two pivotal Phase 3 clinical trials designed to evaluate the investigational oral compound BG-12 as a monotherapy in people with relapsing-remitting multiple sclerosis.

11 Apr 2011

Takeda, Heptares collaborate to develop new drugs against CNS disorders

Heptares Therapeutics and Takeda Pharmaceutical Company today announced the formation of a two-year drug discovery collaboration focused on a single G-protein coupled receptor that plays an important role in the pathology of central nervous system disorders.

11 Apr 2011

Gilenya can reduce risk of disability progression in patients with RRMS

A new analysis demonstrated that Gilenya reduced the risk of disability progression in patients with relapsing-remitting multiple sclerosis, regardless of treatment history. This analysis of the phase III two-year FREEDOMS study is one of 11 abstracts on Gilenya being presented at the 63rd annual meeting of the American Academy of Neurology.

11 Apr 2011

FDA accepts Antares Pharma's Anturol NDA for filing, assigns PDUFA date

Antares Pharma, Inc. today announced the New Drug Application (NDA) for Anturol® Gel in patients with overactive bladder (OAB) was accepted for filing for review by the U.S. Food and Drug Administration (FDA). Anturol is an oxybutynin gel incorporating Antares' ATD Gel technology.

8 Apr 2011

ASBMB honors Stanford professor with DeLano Award for Computational Biosciences

Stanford University professor Axel T. Brunger has been named the winner of the American Society for Biochemistry and Molecular Biology's inaugural DeLano Award for Computational Biosciences. Brunger will present his award lecture, titled "Towards Structural Biology with Single Molecules" at 9:03 a.m. on Wednesday, April 13, at the Experimental Biology 2011 conference at the Walter E. Washington Convention Center in Washington, D.C.

8 Apr 2011

Adult survivors of childhood CNS tumors have persistent, unmet health care needs

Patients treated in childhood for tumours of the central nervous system have persistent and unmet health care needs even in adulthood, according to a comprehensive study from Karolinska Institutet which investigated an entire cohort of patients in Sweden.

8 Apr 2011

A2AAR-selective agonists may prevent permanent vision damage from traumatic optic nerve injury

Scientists want to protect the optic nerve when the eye takes a blow on the battlefield or in a car wreck.

7 Apr 2011

FDA approves Horizant Extended-Release Tablets for Restless Legs Syndrome

GlaxoSmithKline and XenoPort, Inc. announced Wednesday that the U.S. Food and Drug Administration (FDA) has approved Horizant™ (gabapentin enacarbil) Extended-Release Tablets for the treatment of moderate-to-severe primary Restless Legs Syndrome in adults. Horizant is not recommended for patients who are required to sleep during the daytime and remain awake at night.

7 Apr 2011

TZDs might serve as new agents for addiction treatment

Thiazolidinediones are a class of medications that are commonly prescribed to treat type-2 diabetes, while fibrates are a structurally-related class of medications that are prescribed to modulate lipid levels in both diabetic and non-diabetic patients to help reduce the risk of cardiovascular disease.

6 Apr 2011

Retrovirus XMRV may not be associated with Chronic Fatigue Syndrome in the central nervous system

There has been substantial mystery surrounding the origins of Chronic Fatigue Syndrome (CFS), a condition affecting as many as four million Americans and marked by symptoms that include a sense of weariness that sleep does not improve and difficulty with memory and concentration.

6 Apr 2011

Scientists discover new compounds that may help fight against parasitic diseases

Trypanosomatid parasites cause diseases like African sleeping sickness, Chagas' disease and leishmaniasis. Leishmaniasis affects about 12 million people worldwide, mostly in developing countries. Current drug treatments are inadequate due to drug toxicity and resistance.

5 Apr 2011

SMT announces $10.5 million financing to develop novel device for use in TAVI procedures

SMT Research and Development Ltd. of Herzliya Pituach, Israel announced today a significant investment by OrbiMed Advisors LLC. SMT is finalizing the development of a novel embolic protection device designed for use during Transcatheter Aortic Valve Implantation procedures.

4 Apr 2011

ACADIA extends collaboration agreement with Allergan for drug discovery platform

ACADIA Pharmaceuticals Inc., a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it has extended its drug discovery and development collaboration with Allergan, Inc.

1 Apr 2011

Researchers study role of acetylation in Alzheimer's disease

Researchers at the University of Pennsylvania School of Medicine have determined that a well-known chemical process called acetylation has a previously unrecognized association with one of the biological processes associated with Alzheimer's disease and related disorders. The findings were published in the latest issue of Nature Communications.

1 Apr 2011

Invida, Roche partner to commercialize primary care products

Invida Group Pte Ltd, the leading specialty pharmaceutical company focused on the commercialization of healthcare products throughout Asia Pacific, today announced that it has entered into a partnership agreement with Roche for the commercialization and marketing of that company's primary care portfolio throughout Korea.

1 Apr 2011

Omeros announces outcome from OMS103HP Phase 3 study in patients undergoing ACL surgery

Omeros Corporation, a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today reported the outcome from its Phase 3 program evaluating OMS103HP in patients undergoing arthroscopic anterior cruciate ligament reconstruction surgery.

1 Apr 2011

Sleep apnea along with excessive daytime sleepiness elevates risk of death in older adults

A study in the April 1 issue of the journal SLEEP suggests that the risk of death is more than two times higher in older adults who have sleep apnea and report struggling with excessive daytime sleepiness.

1 Apr 2011

New research sheds light on Sudden Infant Death Syndrome

New research published today in The Journal of Physiology sheds light on areas of the brain thought to be the root cause of Sudden Infant Death Syndrome - the poorly understood condition also known as 'cot death'.

1 Apr 2011

Central Nervous System News and Research

Positive results from laquinimod Phase III ALLEGRO study in multiple sclerosis to be presented at AAN

Epilepsy medication USL255 associated with less fluctuation in plasma levels compared to topiramate IR

Positive top-line results from Biogen BG-12 Phase 3 trial in RRMS

Takeda, Heptares collaborate to develop new drugs against CNS disorders

Gilenya can reduce risk of disability progression in patients with RRMS

FDA accepts Antares Pharma's Anturol NDA for filing, assigns PDUFA date

ASBMB honors Stanford professor with DeLano Award for Computational Biosciences

Adult survivors of childhood CNS tumors have persistent, unmet health care needs

A2AAR-selective agonists may prevent permanent vision damage from traumatic optic nerve injury

FDA approves Horizant Extended-Release Tablets for Restless Legs Syndrome

TZDs might serve as new agents for addiction treatment

Retrovirus XMRV may not be associated with Chronic Fatigue Syndrome in the central nervous system

Scientists discover new compounds that may help fight against parasitic diseases

SMT announces $10.5 million financing to develop novel device for use in TAVI procedures

ACADIA extends collaboration agreement with Allergan for drug discovery platform

Researchers study role of acetylation in Alzheimer's disease

Invida, Roche partner to commercialize primary care products

Omeros announces outcome from OMS103HP Phase 3 study in patients undergoing ACL surgery

Sleep apnea along with excessive daytime sleepiness elevates risk of death in older adults

New research sheds light on Sudden Infant Death Syndrome

Event guide: The 7th CNS Drug Delivery Summit eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News